Functional imaging of oxidative stress with a novel PET imaging agent, 18f-5-fluoro-l-aminosuberic acid

Journal of Nuclear Medicine

Volumn 55, Issue 4, 2014, Pages 657-664

  Webster, Jack M ^a   Morton, Christine A ^a   Johnson, Bruce F ^a   Yang, Hua ^b   Rishel, Michael J ^a   Lee, Brian D ^a   Miao, Qing ^b   Pabba, Chittari ^a   Yapp, Donald T ^c,d   Schaffer, Paul ^b  

^a GE GLOBAL RESEARCH   (United States)

^b TRIUMF   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

18F; Functional imaging; Oxidative stress; PET; Tumor imaging

Indexed keywords

5 FLUORO LEVO AMINOSUBERIC ACID F 18; AMINO ACID; CONTRAST MEDIUM; CYSTEINE; FLUORODEOXYGLUCOSE F 18; GLUTAMIC ACID; LEVO AMINOSUBERIC ACID; UNCLASSIFIED DRUG;

AMINO ACID TRANSPORT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD-1 MOUSE; CELL PROLIFERATION; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; ISOTOPE LABELING; KIDNEY CLEARANCE; LYMPHOMA; MOUSE; NONHUMAN; OVARY CARCINOMA; OXIDATIVE STRESS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TISSUE DISTRIBUTION; TUMOR XENOGRAFT;

18F; FUNCTIONAL IMAGING; OXIDATIVE STRESS; PET; TUMOR IMAGING;

AMINO ACIDS, DICARBOXYLIC; ANIMALS; CELL LINE, TUMOR; HUMANS; ISOTOPE LABELING; MICE; MICE, NUDE; NEOPLASM STAGING; NEOPLASMS; OXIDATIVE STRESS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901308160     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.126664     Document Type: Article

References (39)

1. Neels OC, Koopmans KP, Jager PL, et al. Manipulation of [11C]-5-hydroxytryptophan and 6-[18F]fluoro-3,4-dihydroxy-L-phenylalanine accumulation in neuroendocrine tumor cells. Cancer Res. 2008;68:7183-7190.
2. Kasper BS, Struffert T, Kasper EM, et al. 18Fluoroethyl-L-tyrosine-PET in longterm epilepsy associated glioneuronal tumors. Epilepsia. 2011;52:35-44.
3. Ploessl K, Wang L, Lieberman BP, Qu W, Kung HF. Comparative evaluation of 18F-labeled glutamic acid and glutamine as tumor metabolic imaging agents. J Nucl Med. 2012;53:1616-1624.
4. McConathy J, Yu W, Jarkas N, Seo W, Schuster DM, Goodman MM. Radiohalogenated nonnatural amino acids as PET and SPECT tumor imaging agents. Med Res Rev. 2012;32:868-905.
5. Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol. 2005;15:254-266.
6. Bannai S, Kitamura E. Transport interaction of L-cystine and L-glutamate in human diploid fibroblasts in culture. J Biol Chem. 1980;255:2372-2376.
7. Okuno S, Sato H, Kuriyama-Matsumura K, et al. Role of cystine transport in intracellular glutathione level and cisplatin resistance in human ovarian cancer cell lines. Br J Cancer. 2003;88:951-956.
8. Valdovinos-Flores C, Gonsebatt ME. The role of amino acid transporters in GSH synthesis in the blood-brain barrier and central nervous system. Neurochem Int. 2012;61:405-414.
9. Lewerenz J, Hewett SJ, Huang Y, et al. The cystine/glutamate antiporter system xc-in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxid Redox Signal. 2013;18:522-555.
10. Lo M, Wang YZ, Gout PW. The xc-cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J Cell Physiol. 2008;215: 593-602.
11. Conrad M, Sato H. The oxidative stress-inducible cystine/glutamate antiporter, system xc-: cystine supplier and beyond. Amino Acids. 2012;42:231-246.
12. Nguyen T, Nioi P, Pickett CB. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem. 2009;284: 13291-13295.
13. Sasaki H, Sato H, Kuriyama-Matsumura K, et al. Electrophile response elementmediated induction of the cystine/glutamate exchange transporter gene expression. J Biol Chem. 2002;277:44765-44771.
14. Koglin N, Mueller A, Berndt M, et al. Specific PET imaging of xC-transporter activity using a 18F-labeled glutamate derivative reveals a dominant pathway in tumor metabolism. Clin Cancer Res. 2011;17:6000-6011.
15. Baek S, Choi CM, Ahn SH, et al. Exploratory clinical trial of (4S)-4-(3-[18F] fluoropropyl)-L-glutamate for imaging xC-transporter using positron emission tomography in patients with non-small cell lung or breast cancer. Clin Cancer Res. 2012;18:5427-5437.
16. Baek S, Mueller A, Lim YS, et al. (4S)-4-(3-18F-fluoropropyl)-L-glutamate for imaging of xC-transporter activity in hepatocellular carcinoma using PET: preclinical and exploratory clinical studies. J Nucl Med. 2013;54:117-123.
17. Bräuner-Osborne H, Slok FA, Skjaerbaek N, et al. A new highly selective metabotropic excitatory amino acid agonist: 2-amino-4-(3-hydroxy-5- methylisoxazol-4-yl)butyric acid. J Med Chem. 1996;39:3188-3194.
18. Julio-Pieper M, Flor PJ, Dinan TG, Cryan JF. Exciting times beyond the brain: metabotropic glutamate receptors in peripheral and non-neural tissues. Pharmacol Rev. 2011;63:35-58.
19. Ganapathy V, Thangaraju M, Prasad PD. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther. 2009;121:29-40.
20. Ahmadian H, Nielsen B, Brauner-Osborne H, et al. (S)-homo-AMPA, a specific agonist at the mGlu6 subtype of metabotropic glutamic acid receptors. J Med Chem. 1997;40:3700-3705.
21. Lo M, Ling V, Low C, Wang YZ, Gout PW. Potential use of the anti-inflammatory drug, sulfasalazine, for targeted therapy of pancreatic cancer. Curr Oncol. 2010;17:9-16.
22. Narang VS, Pauletti GM, Gout PW, Buckley DJ, Buckley AR. Suppression of cystine uptake by sulfasalazine inhibits proliferation of human mammary carcinoma cells. Anticancer Res. 2003;23:4571-4579.
23. Gout PW, Buckley AR, Simms CR, Bruchovsky N. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the xc-cystine transporter: a new action for an old drug. Leukemia. 2001;15:1633-1640.
24. Gout PW, Simms CR, Robertson MC. In vitro studies on the lymphoma growthinhibitory activity of sulfasalazine. Anticancer Drugs. 2003;14:21-29.
25. Chung WJ, Lyons SA, Nelson GM, et al. Inhibition of cystine uptake disrupts the growth of primary brain tumors. J Neurosci. 2005;25:7101-7110.
26. Ogunrinu TA, Sontheimer H. Hypoxia increases the dependence of glioma cells on glutathione. J Biol Chem. 2010;285:37716-37724.
27. Yoshikawa M, Tsuchihashi K, Ishimoto T, et al. xCT inhibition depletes CD44vexpressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma. Cancer Res. 2013;73:1855-1866.
28. Doxsee DW, Gout PW, Kurita T, et al. Sulfasalazine-induced cystine starvation: potential use for prostate cancer therapy. Prostate. 2007;67:162-171.
29. Guan J, Lo M, Dockery P, et al. The xc-cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine. Cancer Chemother Pharmacol. 2009;64:463-472.
30. Lo M, Ling V, Wang YZ, Gout PW. The xc-cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance. Br J Cancer. 2008;99:464-472.
31. Müerköster S, Arlt A, Witt M, et al. Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer. Int J Cancer. 2003;104:469-476.
32. Chen RS, Song YM, Zhou ZY, et al. Disruption of xCT inhibits cancer cell metastasis via the caveolin-1/beta-catenin pathway. Oncogene. 2009;28:599-609.
33. Ishimoto T, Nagano O, Yae T, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc-and thereby promotes tumor growth. Cancer Cell. 2011;19:387-400.
34. Gupta V, Jani JP, Jacobs S, et al. Activity of melphalan in combination with the glutathione transferase inhibitor sulfasalazine. Cancer Chemother Pharmacol. 1995;36:13-19.
35. Qin S, Colin C, Hinners I, Gervais A, Cheret C, Mallat M. System Xc-and apolipoprotein E expressed by microglia have opposite effects on the neurotoxicity of amyloid-beta peptide 1-40. J Neurosci. 2006;26:3345-3356.
36. Savaskan NE, Heckel A, Hahnen E, et al. Small interfering RNA-mediated xCT silencing in gliomas inhibits neurodegeneration and alleviates brain edema. Nat Med. 2008;14:629-632.
37. Domercq M, Sanchez-Gomez MV, Sherwin C, Etxebarria E, Fern R, Matute C. System xc-and glutamate transporter inhibition mediates microglial toxicity to oligodendrocytes. J Immunol. 2007;178:6549-6556.
38. Albrecht P, Lewerenz J, Dittmer S, Noack R, Maher P, Methner A. Mechanisms of oxidative glutamate toxicity: the glutamate/cystine antiporter system xc-as a neuroprotective drug target. CNS Neurol Disord Drug Targets. 2010;9:373-382.
39. Kumar M, Mosci C, Keu KV, et al. Evaluation of the 18F-labeled L-glutamate derivative 18F-FSPG (BAY 94-9392) in brain and head and neck cancer patients [abstract]. J Nucl Med. 2012;53(suppl):274P.